Masimo Corp
NASDAQ:MASI

Watchlist Manager
Masimo Corp Logo
Masimo Corp
NASDAQ:MASI
Watchlist
Price: 170.65 USD 1.39% Market Closed
Market Cap: 9.1B USD
Have any thoughts about
Masimo Corp?
Write Note

Masimo Corp
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Masimo Corp
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Masimo Corp
NASDAQ:MASI
Current Portion of Long-Term Debt
$39.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-11%
Becton Dickinson and Co
NYSE:BDX
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
63%
CAGR 5-Years
11%
CAGR 10-Years
27%
Boston Scientific Corp
NYSE:BSX
Current Portion of Long-Term Debt
$1.7B
CAGR 3-Years
85%
CAGR 5-Years
5%
CAGR 10-Years
88%
Stryker Corp
NYSE:SYK
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
361%
CAGR 5-Years
33%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
42%
CAGR 5-Years
11%
CAGR 10-Years
26%
Intuitive Surgical Inc
NASDAQ:ISRG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Masimo Corp
Glance View

Market Cap
9.1B USD
Industry
Health Care
Economic Moat
None

Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively. In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.

MASI Intrinsic Value
131.1 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Masimo Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
39.4m USD

Based on the financial report for Sep 28, 2024, Masimo Corp's Current Portion of Long-Term Debt amounts to 39.4m USD.

What is Masimo Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-11%

Over the last year, the Current Portion of Long-Term Debt growth was 34%.

Back to Top